Analytica Revels How PeriCoach® Marked Improvement in Quality of Life, Sexual Function and Continence

Analytica (ASX:ALT) creators of PeriCoach clinical trial data conducted by an independent contract research organisation shows significant improvements in quality of life and sexual function, in conjunction with reduced urinary incontinence and improved pelvic floor strength.

KEY TAKEAWAYS:

• Analytica concludes post-clearance, randomised, controlled clinical trial on version 2 product.
• Superior results to control group in quality of life improvements.
• Resources diverted to gathering evidence of version 3 product performance for licensing deal.
• Trial results to be presented to international urological and sexual health conferences.

The post-approval randomised clinical trial was held in Australia at five specialty continence clinics. The trial studied women undergoing clinician-guided pelvic floor rehabilitation (control) and women engaged in clinician guided pelvic floor rehabilitation with PeriCoach (version 2) to support home exercise between visits.

“Analytica’s version 3 PeriCoach has significant improvements over the version 2 product used in this clinical study. The PeriCoach version 3 has a patent-pending onboard accelerometer and gyroscope which, in combination with the force-sensors allows the system to identify whether or not a woman is performing her exercises correctly. It is estimated that about 50% of women do not perform their pelvic floor exercises correctly and there are several different incorrect techniques. The version 3 will be capable of providing real-time feedback to a woman on whether or not she is exercising correctly. As the PeriCoach movement library grows the system will be then able to provide increasingly customised training to correct a woman’s technique. The version 3 system also has superior quality of life monitoring features and a more structured exercise program, which can gather real-world data at a similar level of rigour to that in the clinical trial.”

“This controlled trial was originally designed to provide evidence to drive clinical acceptance of the PeriCoach,” said Geoff Daly, CEO of Analytica Ltd. “We met this objective and now look to additional studies with the new version 3 which engage the everyday consumer. Having already achieved regulatory clearances in all major markets, collecting credible, publishable, real-world data is underway. Clinical evidence established through strong study designs, as well as how the product performs in the hands of consumers are essential in partner discussions. Over the last year the landscape has shifted and our technology advanced with additional data capture and analysis functionality. All the enhancements and investment into the version 3 PeriCoach have been designed with this focus.”

 Request Information